Please use this identifier to cite or link to this item:
https://doi.org/10.1016/0014-2999(95)00030-O
DC Field | Value | |
---|---|---|
dc.title | 5-Carboxamidotryptamine attenuates the development of deoxycorticosterone acetate-salt hypertension in rats | |
dc.contributor.author | Balasubramaniam, G. | |
dc.contributor.author | Lee, H.S. | |
dc.contributor.author | Mah, S.C. | |
dc.date.accessioned | 2012-04-02T07:42:19Z | |
dc.date.available | 2012-04-02T07:42:19Z | |
dc.date.issued | 1995 | |
dc.identifier.citation | Balasubramaniam, G., Lee, H.S., Mah, S.C. (1995). 5-Carboxamidotryptamine attenuates the development of deoxycorticosterone acetate-salt hypertension in rats. European Journal of Pharmacology 276 (1-2) : 183-190. ScholarBank@NUS Repository. https://doi.org/10.1016/0014-2999(95)00030-O | |
dc.identifier.issn | 00142999 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/32120 | |
dc.description.abstract | The effect of chronic i.v. infusion of the 5-HT1 receptor agonist, 5-carboxamidotryptamine (5-CT), was evaluated during the development of deoxycorticosterone acetate-salt (DOCA-salt) hypertension in rats over 4 weeks. Vehicle-treated ((n = 10) Sprague-Dawley rats given DOCA (100 mg/kg, s.c.) and 1% saline as drinking fluid developed hypertension with systolic blood pressure reaching 194.6 ± 8.99 mmHg at 27 days. In DOCA-salt rats treated with 5-CT infusions (15.0 μg/kg per day, n = 10) for 4 weeks via osmotic minipumps, systolic blood pressure was significantly lower by 41.7 mm Hg at day 27 when compared to vehicle-treated DOCA-salt rats. Systolic blood pressure values on day 27 in 5-CT-treated DOCA-salt rats were however greater than those in vehicle-treated control rats which were not given DOCA. Systolic blood pressure in 5-CT-treated DOCA-salt rats was significantly lower by day 7 compared to vehicle-treated DOCA-salt rats and remained lowered for the rest of the observation period. Heart rate was significantly greater in 5-CT-treated DOCA-salt rats on day 7 when compared to vehicle-treated DOCA-salt rats. Baroreflex sensitivity on day 28 was significantly greater in 5-CT-treated DOCA-salt rats as compared to vehicle-treated DOCA-salt rats. On day 28, hypotensive responses to hexamethonium (20 mg/kg) in 5-CT-treated DOCA-salt rats were markedly reduced compared to those in vehicle-treated DOCA-salt rats. The data suggest that chronic administration of 5-CT attenuates the development of DOCA-salt hypertension in rats with concomitant attenuation of the dampening of baroreffex sensitivity seen during the development of hypertension. The results also suggest a peripheral sympathoinhibitory action of 5-CT in addition to the known peripheral vasodilatation via 5-HT1 receptors. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/0014-2999(95)00030-O | |
dc.source | Scopus | |
dc.subject | (Chronic i.v. infusion) | |
dc.subject | 5-Carboxamidotryptamine | |
dc.subject | Baroreflex sensitivity | |
dc.subject | Blood pressure | |
dc.subject | DOCA-salt (deoxycorticosterone acetate-salt) hypertensive rat | |
dc.type | Article | |
dc.contributor.department | PHARMACOLOGY | |
dc.description.doi | 10.1016/0014-2999(95)00030-O | |
dc.description.sourcetitle | European Journal of Pharmacology | |
dc.description.volume | 276 | |
dc.description.issue | 1-2 | |
dc.description.page | 183-190 | |
dc.description.coden | EJPHA | |
dc.identifier.isiut | A1995QP50300025 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.